Suvorexant carries a slight risk of abuse. Events that suggested possible abuse were identified in 3% to 4% of patients in clinical trials.2,3 Suvorexant is a central nervous system depressant. Rare side effects include sleep paralysis, hypnagogic hallucinations, and mild cataplexy, consisting of brief periods of leg weakness.2 Suvorexant should be avoided in patients with depression because it...

Suvorexant is a novel dual orexin receptor antagonist (DORA) newly introduced in the U.S. as a hypnotic, but no claim of superiority over other hypnotics has been offered.  The manufacturer argued that the 5 and 10 mg starting doses recommended by the FDA might be ineffective.  The manufacturer's main Phase III trials had not even included the 10 mg dosage, and the 5 mg dosage had not been test...

OBJECTIVE We performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia. METHODS Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and s...

s | 39 PT652 Neuropeptide receptor genes polymorphism and sleep disorders V.V. Gafarov1, E.A. Gromova1, M. I. Voevoda1, I.V. Gagulin1, V.N. Maximov1, A.V.Gafarova1, D.O. Panov1 1. FSBI Institute of Internal and Preventive Medicine Abstract Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45–64 years of Novosibirsk. Methods: ...

s | 39 PT652 Neuropeptide receptor genes polymorphism and sleep disorders V.V. Gafarov1, E.A. Gromova1, M. I. Voevoda1, I.V. Gagulin1, V.N. Maximov1, A.V.Gafarova1, D.O. Panov1 1. FSBI Institute of Internal and Preventive Medicine Abstract Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45–64 years of Novosibirsk. Methods: ...

s | 39 PT652 Neuropeptide receptor genes polymorphism and sleep disorders V.V. Gafarov1, E.A. Gromova1, M. I. Voevoda1, I.V. Gagulin1, V.N. Maximov1, A.V.Gafarova1, D.O. Panov1 1. FSBI Institute of Internal and Preventive Medicine Abstract Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45–64 years of Novosibirsk. Methods: ...

Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, SB-649868, suvorexant (MK-4305), and filorexant (MK-6096), have shown promise for the treatment of insomnias and sleep disorders. Whether antagonism of both OX1R and OX2R is necessary for sleep induction has been a matter of some debate. Experiments using knockout mice suggest that it may be sufficient to antagonize only OX2R. T...

Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsine...

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose...

s | 39 PT652 Neuropeptide receptor genes polymorphism and sleep disorders V.V. Gafarov1, E.A. Gromova1, M. I. Voevoda1, I.V. Gagulin1, V.N. Maximov1, A.V.Gafarova1, D.O. Panov1 1. FSBI Institute of Internal and Preventive Medicine Abstract Objective: To study the association gene of candidate NPSR1 rs324981 with sleep disorders in the open population of men 45–64 years of Novosibirsk. Methods: ...